Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study-Reference-Cited by-同舟云学术

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study

Published:2013 Issue:4 Volume:24 Page:359
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Blinman Prunella¹,Gainford Corona²,Donoghoe Mark²,Martyn Julie²,Blomfield Penny³,Grant Peter⁴,Kichenadasse Ganessan⁵,Vaughan Michelle⁶,Brand Alison⁷,Shannon Catherine⁸,Gebski Val²,Stockler Martin²⁹,Friedlander Michael¹⁰

Affiliation:

1. Department of Medical Oncology, Concord Repatriation General Hospital, Sydney, Australia.

2. NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.

3. Department of Obstetrics and Gynaecology, The Royal Hobart Hospital, Hobart, Australia.

4. Department of Gynaecological Oncology, Mercy Hospital for Women, Melbourne, Australia.

5. Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, Australia.

6. Department of Oncology, Christchurch Hospital, Christchurch, New Zealand.

7. Department of Gynaecological Oncology, Westmead Hospital and University of Sydney, Sydney, Australia.

8. Cancer Services, Mater Adult Hospital, Brisbane, Australia.

9. Sydney Cancer Centre, Royal Prince Alfred and Concord Hospitals, Sydney, Australia.

10. Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://synapse.koreamed.org/pdf/10.3802/jgo.2013.24.4.359

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens;Gynecologic Oncology;2021-08

2. HIPEC for Ovarian Cancer: A Controversial Discussion;Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title];2021-05-05

3. Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer;Medicine;2020-09-04

4. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort;Anticancer Research;2020-03

5. Peritonectomy and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: What gynaecological oncologists really think;Australian and New Zealand Journal of Obstetrics and Gynaecology;2019-03-27